Ukupno preživljavanje bolesnika sa nesitnoćelijskim karcinomom pluća nakon hirurškog lečenja

  • Olivera Lončarević Centre for Clinical Pharmacology; Medical Faculty Military Medical Academy, University of Defence, Belgrade, Serbia
  • Slobodan Aćimović Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
  • Jelena Vuković Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
  • Marko Stojisavljević Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
  • Nebojša Marić Military Medical Academy, Clinic for Chest Surgery, Belgrade, Serbia
  • Slobodan Lončarević Military Medical Academy, Clinic for Maxillofacial Surgery, Belgrade, Serbia
  • Marina Petrović Clinical Center „Kragujevac“, Center for Pulmonary Diseases, Kragujevac, Serbia
  • Ivana Milivojević Special Hospital for Lung Disease „Ozren“, Sokobanja, Serbia
  • Gordana Ignjić PHO Hospital „Sveti vračevi“, Department of Pulmonology, Bijeljina, Bosnia and Herzegovina
  • Gordana Milić Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
  • Leonida Mirilo BELhospice – Center for Palliative Care and Palliative Medicine, Belgrade, Serbia
  • Nemanja Rančić Military Medical Academy, Centre for Clinical Pharmacology, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP161226043L
Ključne reči: pluća, nesitnoćelijski karcinom;, adenokarcinom;, karcinom skvamoznih ćelija;, preživljavanje;, recidiv.

Sažetak


Uvod/Cilj. Karcinom pluća je jedan od najčešćih malignih tumora. Oko 80% karcinoma pluća jeste nesitnoćelijski karcinom pluća (NSCLC). Na osnovu patohistoloških karakteristika, najčešći tipovi NSCLC su skvamocelularni karcinom i adenokarcinom. Cilj studije bio je da se analizira preživ­ljavanje bolesnika sa NSCLC na osnovu njihovog patohistološkog tipa i T – primarni tumor, N – regionalni limfni nodusi, M – udaljene metastaze (TNM) stadijuma koji su lečeni hiruški, a nakon toga prema TNM stadijumu hemio­terapijskim protokolima i/ili radioterapijom. Metode. Izvršena je retrospektivna analiza preživljavanja bolesnika sa NSCLC lečenih u Vojnomedicinskoj akademiji u Beogradu u periodu 2010–2015. Ukupan broj bolesnika je bio 85 (27 žena i 58 muškaraca). Rezultati. Kod bolesnika sa skvamocelularnim karcinomom stopa smrtnosti bila je 19,5% kod ukupno 41 bolesnika, dok je kod bolesnika sa adenokarcinomom stopa smrtnosti bila 43,2% kod ukupno 44 bolesnika. Prosečno ukupno preživljavanje bilo je statistički značajno kraće kod bolesnika sa adenokarcinomom u poređenju sa onima koji su imali skvamocelularni karcinom (1605,2 vs. 1304,8 dana; p = 0.005). S druge strane, prosečno ukupno preživljavanje je bilo statistički značajno kraće kod bolesnika sa adenokarcinomom kod kojih se javio recidiv bolesti u poređenju sa bolesnicima sa skvamocelularnim karcinomom kod kojih se takođe javio recidiv (1212,8 vs. 1835,5 dana; p = 0.032). Zaključak. Adenokarcinom je mnogo agresivniji karcinom u poređenju sa skvamocelularnim karcinomom sa kraćim ukupnim preživljavanjem. Potrebne su dodatne studije kako bi se identifikovali faktori rizika za pojavu recidiva bolesti nakon hiruškog lečenja i kako bi se dodatno objasnila uloga tumorskih markera i tehnika molekularne biologije u progresiji bolesti.

Reference

References

American Cancer Society. Cancer facts and figures. 2016. Availa-ble from: http://www.cancer.org/acs/groups/content/@research /do-cuments/document/acspc-047079.pdf

Fenchel K, Sellmann L, Dempke WC. Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res 2016; 5(1): 115–9.

Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortali-ty, Years of Life Lost, Years Lived With Disability, and Disa-bility-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3(4): 524–8.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Can¬cer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage dis-tri¬bution for patients with non-small cell lung cancer: a Na-tional Cancer Database survey. J Thorac Oncol 2010; 5(1): 29–33.

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathol-ogy and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Wal-dron W. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesede, MD: National Cancer Insti-tute; 2009. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/

Milašinović G. Nationality guidelines of good clinical practice: Lung cancer. Belgrade: National Expert Commission for the Development and Implementation of Good Clinical Practice Guide; 2012. (Serbian) Available from: http://www.zdravlje.gov.rs/downloads/2011/Decembar/

Vodici/Vodic%20za%20dijagnostikovanje%20i%20lecenje%

karcinoma%20pluca.pdf

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(5): 584–94.

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Van¬steenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung can-cer. N Engl J Med 2004; 350(4): 351–60.

Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): A systematic review. Thorax 2001; 56(8): 628–38.

Strand T, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Horn¬slien K, et al. Potentially curative radiotherapy for non-small-cell lung cancer in Norway: A population-based study of survival. Int J Radiat Oncol Biol Phys 2011; 80(1): 133–41.

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemo-therapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Can¬cer Inst 1991; 83(6): 417–23.

Durm G, Hanna N. Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 71–81.

Heist RS. First-Line Systemic Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 59–70.

Tam K, Daly M, Kelly K. Treatment of Locally Advanced Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 45–57.

Chuang JC, Liang Y, Wakelee HA. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 31–44.

Park SJ, More S, Murtuza A, Woodward BD, Husain H. New Tar¬gets in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 113–29.

Pisters KM, Le Chevalier T. Adjuvant chemotherapy in com-pletely resected non-small-cell lung cancer. J Clin Oncol 2005; 23(14): 3270–8.

Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6): 1710–7.

Crinò L, Weder W, van Meerbeeck J, Felip E. ESMO Guidelines Working Group. Early stage and locally advanced (non-me¬ta-static) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103–15.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for ad-van¬ced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212–36.

Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, et al. Differences between squamous cell carcinoma and adeno-carcinoma of the lung: Are adenocarcinoma and squamous cell carcinoma prognostically equal. Jpn J Clin Oncol 2012; 42(3): 189–95.

American Cancer Society. Non-small cell lung cancer stages. [cit-ed 2016 May 16]. Available from: http://www.cancer.org/cancer/lungcancer-non-smal¬l-cell/detailedguide/non-small-cell-lung-cancer-survival-rates

Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaki Y, Okuda K, et al. Prognosis of recurrent non-small cell lung cancer fol-lowing complete resection. Med Lett 2014; 7(4): 1300–4.

Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 2014; 3(4): 242–9.

Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011; 140(6): 1494–502.

Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, Yano T, et al. Prog¬nostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. Ann Thorac Surg 2010; 89(3): 864–9.

Objavljeno
2021/01/13
Broj časopisa
Vol. 75 Br. 12 (2018): Vojnosanit pregl
Rubrika
Originalni članak